If life sciences companies address these aspects early, they can successfully plan commercial launches and enable future adaptability.
In brief
- To manage compliance and reduce costs, companies should consider customs and VAT complexities.
- Driven by the COVID-19 pandemic, life sciences companies have focused on increasing supply chain flexibility to reduce future disruption.
- Opportunities exist to yield savings in customs and VAT compliance, specifically when identified early in the supply chain design.
Source EY
Latest Posts in "World"
- VATupdate Newsletter Week 37 2025
- Worldwide Upcoming E-Invoicing mandates, implementations and changes – Chronological
- Peppol – Invoice type code (UNCL1001 subset)
- Navigating the Risks of the use of Digital Reporting and E-Invoicing in the Age of Advanced Fraud Detection
- The Risks of Using Outdated VAT Numbers
